Research Topics
| Maria TzefosSummaryAffiliation: Wingate University Country: USA Publications
|
Detail Information
Publications
3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversyMaria Tzefos
Wingate University School of Pharmacy, Wingate, NC 28174, USA
J Clin Lipidol 5:450-9. 2011..To review efficacy and safety data of 3-hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (also known as statins) in adult patients with chronic liver disease...
Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adultsMaria Tzefos
Cabarrus Family Medicine, Harrisburg, NC, USA
Ann Pharmacother 46:68-78. 2012..To review pharmacologic, pharmacokinetic, efficacy, and safety data of once-weekly glucagon-like peptide-1 (GLP-1) agonists exenatide long-acting release (LAR), albiglutide, and taspoglutide in treatment of type 2 diabetes mellitus (T2DM)...
Fesoterodine for the treatment of overactive bladderMaria Tzefos
School of Pharmacy, Wingate University, Wingate, NC 28174, USA
Ann Pharmacother 43:1992-2000. 2009..To review pharmacologic, pharmacokinetic, efficacy, and safety data for fesoterodine and determine its role in the treatment of overactive bladder...
Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitusMaria Tzefos
School of Pharmacy, Wingate University, NC 28174, USA
Ann Pharmacother 44:1294-300. 2010..To evaluate the efficacy and tolerability of combination glucagon-like peptide-1 (GLP-1) analogs and insulin in the management of type 2 diabetes mellitus (T2DM) in adults...
